Clinical Trial

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This phase Ib/II trial tests the safety, side effects, best dose and how well giving CX-5461 works for the treatment of patients with B-cell non-Hodgkin lymphoma. CX-5461 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving CX-5461 may be safe, tolerable and/or effective in treating patients with B-cell non-Hodgkin lymphoma.
Protocol Amendment History 1 change
notable Trial sites expanded: 4 -> 8 locations 2026-07-23
Trial Details
NCT Number NCT07069699
Lead Sponsor National Cancer Institute (NCI)
Conditions Burkitt Lymphoma, Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
Enrollment 50 participants
Start Date 2026-10-13
Primary Completion 2030-01-31 (estimated)
Study Completion 2030-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-31